Australia markets open in 3 hours 3 minutes

Bellerophon Therapeutics, Inc. (BLPH)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0586+0.0075 (+14.68%)
At close: 02:13PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 625.09k
Enterprise value -14.54M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.10
Price/book (mrq)0.17
Enterprise value/revenue -2.58
Enterprise value/EBITDA 1.32

Trading information

Stock price history

Beta (5Y monthly) 0.68
52-week change 3-99.29%
S&P500 52-week change 323.06%
52-week high 311.1500
52-week low 30.0290
50-day moving average 30.0542
200-day moving average 30.1721

Share statistics

Avg vol (3-month) 345.81k
Avg vol (10-day) 311.65k
Shares outstanding 512.23M
Implied shares outstanding 612.8M
Float 810.2M
% held by insiders 115.03%
% held by institutions 110.39%
Shares short (29 Sept 2023) 490.45k
Short ratio (29 Sept 2023) 41.26
Short % of float (29 Sept 2023) 40.90%
Short % of shares outstanding (29 Sept 2023) 40.74%
Shares short (prior month 31 Aug 2023) 4123.63k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 Feb 2020
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 310 Feb 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin -164.06%
Operating margin (ttm)-195.76%

Management effectiveness

Return on assets (ttm)-78.47%
Return on equity (ttm)-165.96%

Income statement

Revenue (ttm)5.64M
Revenue per share (ttm)0.51
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -11.04M
Net income avi to common (ttm)-9.25M
Diluted EPS (ttm)-0.8900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.38M
Total cash per share (mrq)0.36
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.96
Book value per share (mrq)0.30

Cash flow statement

Operating cash flow (ttm)-12.34M
Levered free cash flow (ttm)-9.7M